DOCSLIB.ORG

DNA Methylation Dysfunction in Chronic Kidney Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DNA Methylation Dysfunction in Chronic Kidney Disease G C A T T A C G G C A T genes Review DNA Methylation Dysfunction in Chronic Kidney Disease Diego Ingrosso 1,* and Alessandra F. Perna 2 1 Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy 2 Department of Medical Translational Sciences, School of Medicine, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; [email protected] * Correspondence: [email protected] Received: 19 May 2020; Accepted: 9 July 2020; Published: 16 July 2020 Abstract: Renal disease is the common denominator of a number of underlying disease conditions, whose prevalence has been dramatically increasing over the last two decades. Two aspects are particularly relevant to the subject of this review: (I) most cases are gathered under the umbrella of chronic kidney disease since they require—predictably for several lustrums—continuous clinical monitoring and treatment to slow down disease progression and prevent complications; (II) cardiovascular disease is a terrible burden in this population of patients, in that it claims many lives yearly, while only a scant minority reach the renal disease end stage. Why indeed a review on DNA methylation and renal disease? As we hope to convince you, the present evidence supports the role of the existence of various derangements of the epigenetic control of gene expression in renal disease, which hold the potential to improve our ability, in the future, to more effectively act toward disease progression, predict outcomes and offer novel therapeutic approaches. Keywords: CKD; ESRD; dialysis; renal failure; DNA methylation; methylation reactions; epigenetic regulation; disease markers 1. Introduction Kidney disease mostly refers to chronic kidney disease (CKD), which is a frequent complication of common metabolic, inflammatory and cardiovascular diseases. CKD represents the bulk of renal failure cases; these conditions evolve chronically in a matter of several years. On the other hand, various predisposing extra-renal (e.g., cardiovascular shock, thrombosis of the renal artery) or renal (e.g., toxic drug-induced tubular necrosis), or urinary (e.g., ureter obstruction) causes may rapidly (days or hours) evolve towards acute kidney injury (AKI), a condition which, if not promptly reversed, may soon require replacement therapy or evolve towards CKD. Various lines of evidence support the existence of epigenetic alterations in CKD, particularly as modifications of DNA methylation either global or at specific sites, or both. The meaning of these alterations, relevant to possible dysfunction of the epigenetic control of gene expression and the issue of their possible implication in the disease progression and the occurrence of CKD complications, are discussed, as well as the potential role of DNA methylation modification as disease markers. This review is organized in chapters, the first of which is dedicated to the epidemiology of renal disease, thus focusing on the global extent of the phenomenon and of its complications, which may as well relate to epigenetics. The subsequent chapters will be dedicated to specific aspects of renal disease and DNA methylation, which are relevant to: (I) anemia and erythropoietin in CKD (II) metabolic and biochemical aspects (e.g., hyperhomocysteinemia (HHcy), a strong cardiovascular risk factor with high Genes 2020, 11, 811; doi:10.3390/genes11070811 www.mdpi.com/journal/genes Genes 2020, 11, 811 2 of 22 prevalence in CKD. (III) Inflammation, fibrosis and disease progression. (IV) Epigenetic alterations of Genesdiagnostic, 2020, 11, x prognostic FOR PEER REVIEW and/or therapeutic potential. (V) Onconephrology. 2 of 22 2. Chronic Kidney Disease: A Worldwide Pandemic 2. Chronic Kidney Disease: A Worldwide Pandemic Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for more than 3 months, with implications for health, monitored by a reduced glomerular present for more than 3 months, with implications for health, monitored by a reduced glomerular filtration rate (GFR) and/or other markers, such as proteinuria [1,2]. Kidney disease is steadily filtration rate (GFR) and/or other markers, such as proteinuria [1,2]. Kidney disease is steadily increasing worldwide, accounting for about 10% of the general population [3,4]. This is due to classical increasing worldwide, accounting for about 10% of the general population [3,4]. This is due to underlying causes, such as glomerulonephritis, as well as to a dramatic increase of a number of classical underlying causes, such as glomerulonephritis, as well as to a dramatic increase of a number highly prevalent noncommunicable diseases, particularly hypertension and diabetes, whose frequent of highly prevalent noncommunicable diseases, particularly hypertension and diabetes, whose complication is kidney end-organ damage (Figure1). frequent complication is kidney end-organ damage (Figure 1). FigureFigure 1. 1. PrevalencePrevalence of of Chronic Chronic Kidney Kidney Disease Disease (CKD (CKD)) and and other other associated associated and and underlying underlying diseases diseases inin the the United United States States of of America. America. Data Data are are from from the the National National Institute Institute of of Diabetes Diabetes and and Digestive Digestive and and KidneyKidney Disease Disease—U.S.—U.S. Department Department of of Health Health and and Human Human Services Services [modifie [modifiedd from: from: [ [5].5]. In In the the pie pie graphgraph CKD CKD accounts accounts for for 13.6 13.6 % % of of the the total total area. area. CKD; CKD; chronic chronic kidney kidney disease. disease. DM; DM; diabetes diabetes mellitus. mellitus. CVD;CVD; cardiovascular cardiovascular disease. disease. TheThe endpoint inin the the clinical clinical history history of CKD of patientsCKD patients is end-stage is end renal-stage disease renal (ESRD), disease characterized (ESRD), 2 characterizedby a GFR <15 by mL a/ minGFR/1.73 <15 mmL/, themin retention/1.73 m2, of the at retention least 88 di offferent at least solutes 88 different (so-called solutes “uremic (so toxins”)-called “uremicand, eventually, toxins”) and, the needeventually, for renal the replacementneed for renal therapy replacement (dialysis therapy or transplantation) (dialysis or transplantation) [6]. This is a [6].clinically-defined This is a clinically situation,-defined see situation, [2], affecting see only[2], affecting about 1% o ofnly overall about CKD 1% of patients, overall characterized CKD patients, by characterizedthe uremic syndrome, by the uremic i.e., the syndrome, terminal clinical i.e., the manifestation terminal clinical of kidney manifestation failure, frequently of kidney including failure, an frequentlyassociation including of signs andan association symptoms of related signs toand the symptoms CKD complications related to the listed CKD in Tablecomplications1. Most of listed CKD inpatients Table 1. are Most indeed of C affKDected patients by a high, are indeed premature affected death by rate a duehigh, to premature these complications, death rate as due discussed to these in complications,the next paragraphs as discussed [2,3]. in the next paragraphs [2,3]. CKD is characterized by many frequent complications, which often threaten the patients’ lives (Table 1). Many, if not all, CKD complications have been associated with altered DNA methylation patters and/or deranged expression of epigenetically regulated genes by DNA methylation. In some cases, these findings suggest new potential therapeutic strategies. The availability of modern molecular biology nanobiotechnologies prompted substantial improvements in the study of DNA methylation in various diseases, thus including CKD, since the turn of this millennium, as described in the following sessions. In Table 1, all common complications in CKD are listed. Anemia and cardiovascular disease (CVD) are particularly important because anemia is almost constantly associated with CKD and requires careful intervention in order to restore hematocrit to an acceptable Genes 2020, 11, 811 3 of 22 Table 1. CKD complications. Parameters/Symptoms/ Complication Related Lab Markers Prevention/Therapy Ref. Nosological Entities Fatigue Low Hb conc • Anemia • Dyspnoea Erythropoietin [7] Low Ht • • Hypoxia • Dyslipidemia CVD events (myocardial infarction, Control of cardiovascular risk Cardiovascular disease (CVD) Hyperhomocysteinemia Other [8] stroke, thrombosis) factors metabolic alterations Hyperkalemia Heart dysfunction (ECG abnormalities, Specific electrolyte correction Electrolyte imbalance • [9] Hyponatriemia (*) arrhythmias) (cation exchange resins; diuretics) • Diuretics Increased plasma volume; • • (furosemide, tolvaptan) Fluid retention Decreased plasma oncotic Edema [10] • Dialysis (end-stage pressure from protein loss • renal disease) Arthritis • Xanthine oxidase inhibitors Gout High uric acid (**) Kidney stones [11] • (allopurinol, febuxostat) CVD risk factor • Organ injury (headache, chest and bone Arterial Blood Gas (ABG) alterations pain, palpitation, dyspnoea, nausea, Specific therapy based on correction Metabolic acidosis (low pH, low bicarbonate, low BE, vomiting, weakness, and bone pain. [12] of pH and bicarbonate alterations. compensatory low paCO2) anxiety, mental derangements, seizures, coma, heart arrhythmia. Phosphate binders (Sevelamer; • High PTH aluminum hydroxide); • Secondary hyperparathyroidism
Load more

Recommended publications
  • Label-Free Proteomic Methodology for the Analysis of Human Kidney Stone Matrix Composition Frank A
    Witzmann et al. Proteome Science (2016) 14:4 DOI 10.1186/s12953-016-0093-x METHODOLOGY Open Access Label-free proteomic methodology for the analysis of human kidney stone matrix composition Frank A. Witzmann1*, Andrew P. Evan2, Fredric L. Coe3, Elaine M. Worcester3, James E. Lingeman4 and James C. Williams Jr2 Abstract Background: Kidney stone matrix protein composition is an important yet poorly understood aspect of nephrolithiasis. We hypothesized that this proteome is considerably more complex than previous reports have indicated and that comprehensive proteomic profiling of the kidney stone matrix may demonstrate relevant constitutive differences between stones. We have analyzed the matrices of two unique human calcium oxalate stones (CaOx-Ia and CaOx-Id) using a simple but effective chaotropic reducing solution for extraction/solubilization combined with label-free quantitative mass spectrometry to generate a comprehensive profile of their proteomes, including physicochemical and bioinformatic analysis.` Results: We identified and quantified 1,059 unique protein database entries in the two human kidney stone samples, revealing a more complex proteome than previously reported. Protein composition reflects a common range of proteins related to immune response, inflammation, injury, and tissue repair, along with a more diverse set of proteins unique to each stone. Conclusion: The use of a simple chaotropic reducing solution and moderate sonication for extraction and solubilization of kidney stone powders combined with label-free quantitative mass spectrometry has yielded the most comprehensive list to date of the proteins that constitute the human kidney stone proteome. Keywords: Calcium oxalate, Kidney stone, Label-free quantitative liquid chromatography–tandem mass spectrometry, Matrix protein, Nephrolithiasis, Proteomics Background deposition is the primary event, at least in the formation The organic matrix within urinary stones has long been of CaOx stones over plaque.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • SHROOM3 Is a Novel Candidate for Heterotaxy Identified by Whole Exome Sequencing Tariq Et Al
    SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing Tariq et al. Tariq et al. Genome Biology 2011, 12:R91 http://genomebiology.com/2011/12/9/R91 (21 September 2011) Tariq et al. Genome Biology 2011, 12:R91 http://genomebiology.com/2011/12/9/R91 RESEARCH Open Access SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing Muhammad Tariq1, John W Belmont2, Seema Lalani2, Teresa Smolarek3 and Stephanie M Ware1,3* Abstract Background: Heterotaxy-spectrum cardiovascular disorders are challenging for traditional genetic analyses because of clinical and genetic heterogeneity, variable expressivity, and non-penetrance. In this study, high-resolution SNP genotyping and exon-targeted array comparative genomic hybridization platforms were coupled to whole-exome sequencing to identify a novel disease candidate gene. Results: SNP genotyping identified absence-of-heterozygosity regions in the heterotaxy proband on chromosomes 1, 4, 7, 13, 15, 18, consistent with parental consanguinity. Subsequently, whole-exome sequencing of the proband identified 26,065 coding variants, including 18 non-synonymous homozygous changes not present in dbSNP132 or 1000 Genomes. Of these 18, only 4 - one each in CXCL2, SHROOM3, CTSO, RXFP1 - were mapped to the absence-of- heterozygosity regions, each of which was flanked by more than 50 homozygous SNPs, confirming recessive segregation of mutant alleles. Sanger sequencing confirmed the SHROOM3 homozygous missense mutation and it was predicted as pathogenic by four bioinformatic tools. SHROOM3 has been identified as a central regulator of morphogenetic cell shape changes necessary for organogenesis and can physically bind ROCK2, a rho kinase protein required for left-right patterning.
    [Show full text]
  • Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD
    CLINICAL EPIDEMIOLOGY www.jasn.org Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD ʈ ʈ Anna Ko¨ttgen,* Shih-Jen Hwang,†‡ Martin G. Larson,§ Jennifer E. Van Eyk, Qin Fu, Emelia J. Benjamin,†¶ Abbas Dehghan,** Nicole L. Glazer,†† W.H. Linda Kao,* ʈʈ Tamara B. Harris,‡‡ Vilmundur Gudnason,§§ Michael G. Shlipak,¶¶ Qiong Yang,§ Josef Coresh,* Daniel Levy,†‡ and Caroline S. Fox†‡*** *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; †Framingham Heart Study, Framingham, Massachusetts; ‡Center for Population Studies, National Heart, Lung, and Blood Institute, and ‡‡Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, Maryland; Departments of §Biostatistics and ʈ ¶Epidemiology, Boston University School of Public Health, Boston, Massachusetts; Department of Medicine, Johns Hopkins University, Baltimore, Maryland; **Department of Epidemiology, Erasmus Medical Centre, Rotterdam, Netherlands; ††Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, ʈʈ Washington; §§Icelandic Heart Association Research Institute, Kopavogur, Iceland; University of Iceland, Reykjavik, Iceland; ¶¶General Internal Medicine Division, San Francisco VA Medical Center, University of California, San Francisco, California; and ***Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts ABSTRACT Common variants in the region of the UMOD gene, which encodes uromodulin (Tamm-Horsfall protein), associate with chronic kidney disease (CKD) and estimated GFR (eGFR). Whether uromodulin levels associate with UMOD variants or with the risk for developing CKD is unknown. We conducted an age- and gender- matched case-control study (n ϭ 200) of incident CKD (eGFR Ͻ60 ml/min per 1.73 m2) within the Framingham Heart Study (FHS).
    [Show full text]
  • Autosomal Dominant Tubulointerstitial Kidney Disease Genotype And
    www.nature.com/scientificreports OPEN Autosomal dominant tubulointerstitial kidney disease genotype and phenotype correlation in a Chinese cohort Kunjing Gong1,2,3,4, Min Xia1,2,3,4, Yaqin Wang1,2,3,4, Na Wang1,2,3,4, Ying Liu1,2,3,4, Victor Wei Zhang5,6, Hong Cheng 7 & Yuqing Chen1,2,3,4* Genes of UMOD, HNF1B, MUC1, REN and SEC61A1 were reported to be associated with autosomal dominant tubulointerstitial kidney disease (ADTKD). 48 probands and their family members (N = 27) were enrolled in this genetic screening study. A combination of methods was employed for comprehensive molecular analysis of both copy number variations (CNVs) and single nucleotide variants (SNVs). 35 probands were followed for years. The phenotype-genotype and genotype- outcome correlation were inferred from these datasets. In this cohort, 18 probands were diagnosed with ADTKD, according to Kidney Disease: Improving Global Outcomes (KDIGO) guideline. Moreover, 11 probands were diagnosed with ADTKD-UMOD, one with ADTKD-REN and one with ADTKD-HNF1B, based on molecularly confrmed pathogenic variants. The 11 UMOD variants were mainly located in codons 28 to 289 and half of the variants were found to change the cysteine amino acid. According to the follow-up data, suspected ADTKD individuals had a better prognosis compared to ADTKD individuals (p = 0.029). Individuals with a cysteine substitution in the UMOD gene appeared to have a better prognosis than individuals with other amino acid substitutions (p = 0.015). Autosomal dominant tubulointerstitial kidney disease (ADTKD) is considered to be one of the common causes of end stage renal disease (ESRD), especially in people whereby familial aggregation is observed1.
    [Show full text]
  • Clinical and Genetic Associations of Renal Function and Diabetic Kidney Disease in the United Arab Emirates: a Cross-Sectional Study
    Open access Research BMJ Open: first published as 10.1136/bmjopen-2017-020759 on 14 December 2018. Downloaded from Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: a cross-sectional study Wael M Osman,1 Herbert F Jelinek,2,3 Guan K Tay,1,4,5,6 Ahsan H Khandoker,6 Kinda Khalaf,6 Wael Almahmeed,7,8 Mohamed H Hassan,9 Habiba S Alsafar1,6 To cite: Osman WM, Jelinek HF, ABSTRACT Strengths and limitations of this study Tay GK, et al. Clinical and Objectives Within the Emirati population, risk factors and genetic associations of genetic predisposition to diabetic kidney disease (DKD) ► This cross-sectional study to determine the clini- renal function and diabetic have not yet been investigated. The aim of this research kidney disease in the United cal, laboratory and genetic associations of diabetic was to determine potential clinical, laboratory and reported Arab Emirates: a cross- kidney disease (DKD) and renal function traits in a genetic loci as risk factors for DKD. sectional study. BMJ Open sample of patients with type 2 diabetes mellitus was Research design and methods Four hundred and ninety 2018;8:e020759. doi:10.1136/ the first of its kind in a population of Arab ancestry unrelated Emirati nationals with type 2 diabetes mellitus bmjopen-2017-020759 from the United Arab Emirates. (T2DM) were recruited with and without DKD, and clinical ► A limitation inherent to this study was that the anal- ► Prepublication history for and laboratory data were obtained. Following adjustments this paper is available online.
    [Show full text]
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
    [Show full text]
  • Identification of a Thymus Microrna‑Mrna Regulatory Network in Down Syndrome
    MOLECULAR MEDICINE REPORTS 20: 2063-2072, 2019 Identification of a thymus microRNA‑mRNA regulatory network in Down syndrome MIAO CHAI*, LIJU SU*, XIAOLEI HAO, MENG ZHANG, LIHUI ZHENG, JIABING BI, XIAO HAN and CHUNBO GAO Department of Clinical Laboratory, The First Hospital of Harbin, Harbin, Heilongjiang 150010, P.R. China Received September 6, 2017; Accepted August 28, 2018 DOI: 10.3892/mmr.2019.10433 Abstract. The present bioinformatics analysis was performed reported in the present study. miR‑30c, miR‑145, miR‑183 and using a multi-step approach to identify a microRNA their targets may serve important roles in the pathogenesis and (miR)-mRNA regulatory network in Down syndrome. miR development of complications in Down syndrome. However, (GSE69210) and mRNA (GSE70573) data was downloaded further experimental studies are required to verify these and collected from the thymic tissues of both Down syndrome results. and karyotypically normal subjects and placed in a public repository. Then, weighted gene co-expression network anal- Introduction ysis (WGCNA) was performed to screen for miRs and mRNAs associated with Down syndrome. Subsequently, differen- Down syndrome is one of the most frequently occurring tially expressed miRs (DEmiRs) and mRNAs/differentially chromosomal abnormalities in humans, with a worldwide inci- expressed genes (DEGs) were identified following screening dence of ~1:1,000 births annually (1). This disease is caused and mapping to RNA data. Bidirectional hierarchical clus- by the presence of part or a full extra copy of chromosome 21 tering analysis was then performed to distinguish DEmiRs and therefore is also called trisomy 21 (2). Down syndrome and DEGs between Down syndrome samples and normal is typically associated with craniofacial abnormalities, intel- control samples.
    [Show full text]
  • Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD
    CLINICAL RESEARCH www.jasn.org Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD Jeremy W. Prokop,1,2 Nan Cher Yeo,3 Christian Ottmann,4,5 Surya B. Chhetri,1,6 Kacie L. Florus,1 Emily J. Ross,1,7 Nadiya Sosonkina,1 Brian A. Link,8 Barry I. Freedman,9 Candice J. Coppola,6 Chris McDermott-Roe,10 Seppe Leysen,4 Lech-Gustav Milroy,4 Femke A. Meijer,4 Aron M. Geurts,10 Frank J. Rauscher III,11 Ryne Ramaker,1 Michael J. Flister,10 Howard J. Jacob,1 Eric M. Mendenhall,1,6 and Jozef Lazar1 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Interpreting genetic variants is one of the greatest challenges impeding analysis of rapidly increasing volumes of genomic data from patients. For example, SHROOM3 is an associated risk gene for CKD, yet causative mechanism(s) of SHROOM3 allele(s) are unknown. Methods We used our analytic pipeline that integrates genetic, computational, biochemical, CRISPR/Cas9 editing, molecular, and physiologic data to characterize coding and noncoding variants to study the human SHROOM3 risk locus for CKD. Results We identified a novel SHROOM3 transcriptional start site, which results in a shorter isoform lacking the PDZ domain and is regulated by a common noncoding sequence variant associated with CKD (rs17319721, allele frequency: 0.35). This variant disrupted allele binding to the transcription factor TCF7L2 in podocyte cell nuclear extracts and altered transcription levels of SHROOM3 in cultured cells, potentially through the loss of repressive looping between rs17319721 and the novel start site.
    [Show full text]
  • Genome Wide Association of Chronic Kidney Disease Progression: the CRIC Study (Author List and Affiliations Listed at End of Document)
    SUPPLEMENTARY MATERIALS Genome Wide Association of Chronic Kidney Disease Progression: The CRIC Study (Author list and affiliations listed at end of document) Genotyping information page 2 Molecular pathway analysis information page 3 Replication cohort acknowledgments page 4 Supplementary Table 1. AA top hit region gene function page 5-6 Supplementary Table 2. EA top hit region gene function page 7 Supplementary Table 3. GSA pathway results page 8 Supplementary Table 4. Number of molecular interaction based on top candidate gene molecular networks page 9 Supplementary Table 5. Results of top gene marker association in AA, based on EA derived candidate gene regions page 10 Supplementary Table 6. Results of top gene marker association in EA, based on AA derived candidate gene regions page 11 Supplementary Table 7. EA Candidate SNP look up page 12 Supplementary Table 8. AA Candidate SNP look up page 13 Supplementary Table 9. Replication cohorts page 14 Supplementary Table 10. Replication cohort study characteristics page 15 Supplementary Figure 1a-b. Boxplot of eGFR decline in AA and EA page 16 Supplementary Figure 2a-l. Regional association plot of candidate SNPs identified in AA groups pages 17-22 Supplementary Figure 3a-f. Regional association plot of candidate SNPs identified in EA groups pages 23-25 Supplementary Figure 4. Molecular Interaction network of candidate genes for renal, cardiovascular and immunological diseases pages 26-27 Supplementary Figure 5. Molecular Interaction network of candidate genes for renal diseases pages 28-29 Supplementary Figure 6. ARRDC4 LD map page 30 Author list and affiliations page 31 1 Supplemental Materials Genotyping Genotyping was performed on a total of 3,635 CRIC participants who provided specific consent for investigations of inherited genetics (of a total of 3,939 CRIC participants).
    [Show full text]
  • Investigating the Role of Shroom3 in Kidney Development
    INVESTIGATING THE ROLE OF SHROOM3 IN KIDNEY DEVELOPMENT INVESTIGATING THE ROLE OF SHROOM3 IN KIDNEY DEVELOPMENT By Ashmeet Hunjan, B.Sc. (Hons.) A Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree Master of Science McMaster University © Copyright by Ashmeet Hunjan, August 2021 ii TITLE: Investigating the Role of Shroom3 in Kidney Development AUTHOR: Ashmeet Hunjan B.Sc. (Hons.), McMaster University PROGRAM: Medical Sciences Graduate Program, Division of Cancer and Genetics, McMaster University, Hamilton, Ontario Canada SUPERVISOR: Darren Bridgewater, PhD SUPERVISORY COMMITTEE: Dr. Joan Krepinsky and Dr. Peter Margetts NUMBER OF PAGES: xiii, 117 iii ABSTRACT Nephrons develop from a specialized group of mesenchyme cells known as the nephron progenitors. Nephron progenitors can very dynamic as they can self-renew, migrate, and change their cell morphology. These alterations are essential for orientating and organizing select cells for progression through various stages of nephrogenesis. However, the underlying mechanisms that drive these dynamic morphological changes are not fully understood. Shroom3 is an actin-binding protein that regulates cell shape changes by modulating the actin cytoskeleton. In mice and humans, mutations in Shroom3 are associated with poor nephron function and chronic kidney disease. Despite these findings, the underlying mechanisms of Shroom3 function and how genetic mutations contribute to abnormal nephron formation are unclear. Here, we investigated functional roles for Shroom3 in the nephron progenitor population by analyzing E13.5 and E18.5 Wildtype and Shroom3 deficient mice (termed Shroom3-/-). First, using in-situ hybridization (ISH) and immunofluorescence (IF), we confirm Shroom3 expression in select nephron progenitors.
    [Show full text]
  • Agricultural University of Athens
    ΓΕΩΠΟΝΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΤΩΝ ΖΩΩΝ ΤΜΗΜΑ ΕΠΙΣΤΗΜΗΣ ΖΩΙΚΗΣ ΠΑΡΑΓΩΓΗΣ ΕΡΓΑΣΤΗΡΙΟ ΓΕΝΙΚΗΣ ΚΑΙ ΕΙΔΙΚΗΣ ΖΩΟΤΕΧΝΙΑΣ ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ ΑΘΗΝΑ 2020 ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Genome-wide association analysis and gene network analysis for (re)production traits in commercial broilers ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ Τριμελής Επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Επταμελής εξεταστική επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Πηνελόπη Μπεμπέλη (Καθ. ΓΠΑ) Δημήτριος Βλαχάκης (Επ. Καθ. ΓΠΑ) Ευάγγελος Ζωίδης (Επ.Καθ. ΓΠΑ) Γεώργιος Θεοδώρου (Επ.Καθ. ΓΠΑ) 2 Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Περίληψη Σκοπός της παρούσας διδακτορικής διατριβής ήταν ο εντοπισμός γενετικών δεικτών και υποψηφίων γονιδίων που εμπλέκονται στο γενετικό έλεγχο δύο τυπικών πολυγονιδιακών ιδιοτήτων σε κρεοπαραγωγικά ορνίθια. Μία ιδιότητα σχετίζεται με την ανάπτυξη (σωματικό βάρος στις 35 ημέρες, ΣΒ) και η άλλη με την αναπαραγωγική
    [Show full text]